



# Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company

CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2020-21

18<sup>th</sup> December, 2020

Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
P.J. Towers, Dalal Street, Fort,  
Mumbai - 400001 (M.H.)

**BSE CODE: 524470**

**Sub: Outcome of the Meeting of the Board of directors held on 18<sup>th</sup> December, 2020 relating to raising of funds by way of issuance of Warrants Convertible into equity shares of the Company and other related matters.**

Dear Sir/Madam,

This has in reference to our letter No. SYNCOM/SE/2020-21 dated 15<sup>th</sup> December, 2020 for notice under Regulation 29(1)(a) of SEBI (LODR) Regulations, 2015 read with Regulation 30 and 83 of SEBI (LODR) Regulations, 2015 and Schedule III of the said Regulations, by which it was informed that meeting No. 5/2020-21 of the Board of directors of the Company is to be held on **Friday, 18<sup>th</sup> December, 2020, at 4.00 P.M.**


We would like to inform that the Board of Directors of the Company at the aforesaid Board meeting have decided and approved the following businesses;

1. Increase in the authorised share capital of the Company from Rs. 80.00 Crores divided into 80.00 Crores Equity Shares of Rs. 1/- each to Rs. 95.00 Crores divided into 95.00 Crores equity shares of Rs. 1/- each subject to the approval of members.
2. Alteration of the Clause V of the Memorandum of Association of the Company to give effect of the increase in the authorised share capital subject to the approval of members.
3. Substitute the existing Articles of Association of the Company with the new Articles of Association to align as per provisions of the Companies Act, 2013 subject to the approval of members.
4. Approval for issuance of upto 15,93,47,820 warrants of Rs.2.53 convertible into upto 15,93,47,820 equity shares of Rs.1.00 at a premium of Rs. 1.53 per share in one or more tranches within a period of 18 (Eighteen) months from the date of allotment of warrants to the Promoter and Promoter Group on preferential basis subject to the approval of members by Special Resolution as per provisions of the SEBI (ICDR) Regulations, 2018 and the SEBI (LODR) Regulations, 2015.
5. Approval for notice of the 1/2020-21 Extra Ordinary General Meeting of the members of the Company to seek approval of the aforesaid Item No. 1 to 4 on Tuesday the 12<sup>th</sup> Day of January, 2021 at the Registered Office of the Company situated at 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East) Mumbai 400093 at 2:00 P.M. through the physical presence of members at the venue as well as providing facility to participate in the Meeting through the Audio/Video Mode and Remote E-voting process.
6. Expansion cum Modernisation of the manufacturing facilities of the plant of the Company situated at 256-257 Industrial Area, Sector 1 Pithampur, District Dhar (M.P.) with the capex investments about Rs. 4031.50 Lakhs only.

You are requested to please take on record our above said information for your reference and record and disseminate on the portal of the BSE for information to the investors and members of the Company.

Thanking you,  
Yours faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED

  
**SHUBHAM DUBEY**  
COMPANY SECRETARY &  
COMPLIANCE OFFICER



*Bringing a smile on every face...*